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Introduction: Treatment for metastatic colorectal cancer (mCRC), employing various schedules, 
combinations, and regimens utilizing 5-ﬂ  uorouracil (5-FU), irinotecan, oxaliplatin, capecitabine, 
bevacizumab, and cetuximab, currently achieves an overall survival that extends to approximately 
two years. Major questions regarding optimal management of mCRC await resolution.
Methods: A thorough review was conducted of all mCRC abstracts, posters, and other presenta-
tions at the 2007 meeting of the American Society of Clinical Oncology (ASCO). Information 
was analyzed in relationship to previously published research to determine the potential impact 
of new data on current and future mCRC management strategies and patient outcomes. Updated 
data presented at ASCO 2008 relevant to these ﬁ  ndings was also analyzed.
Discussion: Ongoing challenges in mCRC treatment include deﬁ  ning the optimal role of 
targeted agents such as cetuximab and bevacizumab, elaborating the mechanisms underlying 
their toxicities, resolving the beneﬁ  ts of adjuvant and neoadjuvant chemotherapy in patients 
who are candidates for surgical resection, establishing whether there are substantive differences 
between sequential and combination chemotherapy regimens, and determining the safety and 
tolerability of chemotherapy in elderly subjects.
Conclusion: Recent reports presented at ASCO 2007 and 2008 indicate incremental improve-
ments in care of patients with mCRC. Nevertheless, irinotecan, oxaliplatin, 5-FU, and to an 
increasing extent the targeted biologic agents bevacizumab and cetuximab continue unchallenged 
as ﬁ  rst-line and later selections.
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Introduction
The annual meeting of the American Society of Clinical Oncology (ASCO) provides 
members of the international oncology community with vital educational exposure to 
the newest developments in chemotherapy for metastatic colorectal cancer (mCRC). The 
most recent meeting, in June 2007, highlighted important presentations from a number 
of European investigators and their American counterparts, with practical implications 
for improving the standard of cancer treatment and for increasing our understanding of 
the clinical potential contained in a burgeoning array of chemotherapy combinations and 
surgical strategies. Presentations describing the capabilities of newer agents and treat-
ment-associated toxicities of these and more familiar agents were also of great interest 
and are discussed here. (Note that this article does not attempt to present complete 
investigator ﬁ  ndings but to highlight areas of compelling interest. In many instances, 
due to time and space constraints inherent in written abstracts and oral presentations, 
P values, conﬁ  dence intervals, and other statistical information are not available).
EPOC
In plenary session, the European Organisation for Research and Treatment of Cancer 
(EORTC) presented ﬁ  nal results of the EPOC (Eloxatin Peri-Operative Chemotherapy) Clinical and Experimental Gastroenterology 2009:2 14
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study, a randomized phase III evaluation of the beneﬁ  t of 
perioperative oxaliplatin, leucovorin (LV), and 5-ﬂ  uorouracil 
(5-FU) (FOLFOX4) chemotherapy.1 The primary objective 
of EPOC was to demonstrate an improvement in progression-
free survival (PFS) with an initial treatment strategy that 
incorporated perioperative FOLFOX4 chemotherapy plus 
surgery compared with surgery alone. A notable aspect 
of this study was its pragmatic approach to the timing of 
chemotherapy: by design, there was no attempt to establish 
the superiority of either pre-operative or post-operative timing 
of administration.2 Rather, the investigators accommodated 
their investigation to the unique beneﬁ  ts of chemotherapy 
associated with each phase. Preoperative administration 
presumably confers beneﬁ  ts by shrinking tumor burden, 
thereby increasing the likelihood of smaller resectable 
masses and allowing the chemoresponsiveness of the tumor 
to be assessed. Postoperative administration targets dormant 
malignant cells in the hepatic remnant and is essentially an 
iteration of chemotherapy for stage III disease, with its known 
attendant beneﬁ  ts.2
In EPOC, over a four-year period, 364 patients were 
randomly assigned to perioperative FOLFOX4 (six cycles 
before and six cycles after surgery) or surgery alone. The 
primary endpoint was PFS, with a projected goal of increasing 
median PFS by 40% (equivalent to a hazard ratio [HR] of 
0.71). Comparable proportions of patients in each treatment 
group could not undergo resection, based on pre-operative 
imaging. In the chemotherapy arm, 151 patients were resected 
after a median of six preoperative cycles, and of these patients, 
115 (63%) underwent postoperative chemotherapy (also 
given for a median of six cycles). Perioperative chemotherapy 
improved PFS in patients with resectable hepatic lesions, and 
PFS improved even more in patients whose metastases were 
successfully resected,2 achieving a 9.2% absolute difference 
in PFS at three years.1 Perioperative chemotherapy was safe, 
raising the possibility that this regimen warrants consider-
ation as a new treatment standard.2 However, both the amount 
of accrual time and the high number of participating centers, 
with likely differences in liver surgery experience among the 
numerous teams, are weaknesses of this study. Furthermore, 
it should be emphasized that neoadjuvant chemotherapy 
before liver surgery is not completely safe, because in this 
study, it clearly increased the percentage of biliary ﬁ  stulae 
(7.5% versus 2.9%).
Results of the EPOC study are certain to elicit vigorous 
discussion, particularly as updated efﬁ  cacy results of the 
MOSAIC (Multicenter International Study of Oxaliplatin/
5FU-LV in the Adjuvant Treatment of Colon Cancer) study 
were also presented at the meeting. The MOSAIC study 
evaluated classical post-operative adjuvant therapy with 
FOLFOX4 in 2246 patients with completely resected stage 
II or III CRC and no prior chemotherapy.3 While MOSAIC 
was initially designed to evaluate the effects of FOLFOX4 
on three-year disease-free survival (DFS), updated results 
for overall survival (OS) at longer intervals showed that 
FOLFOX4 achieved DFS beneﬁ  ts that were maintained at 
3, 5, and 6 years, with no increase in the rate of secondary 
cancers.3,4
Findings from studies such as EPOC and MOSAIC 
suggest a need for future trials that attempt a deﬁ  nitive com-
parison between neoadjuvant and adjuvant chemotherapy. 
Ongoing investigations comparing perioperative FOLFOX 
in combination with targeted biologic agents (cetuximab and 
bevacizumab; EORTC Trial 40051) were discussed by the 
EORTC investigators.2
CRYSTAL, EPIC, and NCIC 
CTG CO.17
Cetuximab, a monoclonal antibody that speciﬁ  cally targets 
epidermal growth factor receptor (EGFR), was the focus 
of presentations reporting on three phase III clinical trials 
(CRYSTAL, EPIC, and CO.17). Both the CRYSTAL 
(Cetuximab combined with iRinotecan in ﬁ  rst-line therapY 
for metaSTatic colorectaL cancer) and EPIC (European 
Prospective Investigation of Cancer) trials demonstrated that 
the addition of cetuximab to a standard irinotecan-containing 
regimen was associated with signiﬁ  cant improvements on 
a number of outcome measures, including OS, PFS, tumor 
shrinkage, and patient quality of life.
CRYSTAL investigated the effectiveness of cetuximab 
in combination with standard irinotecan plus infusional 
5-FU/LV (FOLFIRI) compared with FOLFIRI alone for ﬁ  rst-
line treatment of patients with metastatic, EGFR-expressing 
colorectal cancer.5 Patients were randomly assigned to cetux-
imab (400 mg/m2 initial dose, then 250 mg/m2/week) plus 
bi-weekly FOLFIRI (irinotecan 180 mg/m2, LV 400 mg/m2, 
5-FU bolus 400 mg/m2, 5-FU infusion 2400 mg/m2 over 
46 hours) or FOLFIRI alone. The primary endpoint was 
PFS; secondary endpoints included overall response rate, 
disease control rates, OS, quality of life, and safety. The 
CRYSTAL trial met its primary objective, demonstrating 
that the addition of cetuximab to FOLFIRI for ﬁ  rst-line 
treatment of EGFR-positive mCRC signiﬁ  cantly increased 
PFS, with a 15% risk reduction for progression in patients 
treated with the combination.5 In addition, FOLFIRI plus 
cetuximab was associated with a signiﬁ  cantly higher response Clinical and Experimental Gastroenterology 2009:2 15
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rate (46.9% versus 38.7%, P = 0.0038).6 In subsequent 
analysis, the investigators demonstrated that patients with 
initially unresectable disease who received FOLFIRI plus 
cetuximab had threefold higher radical (R0) resection rates 
in comparison with patients receiving FOLFIRI alone, and 
patients with liver metastases as the only metastatic site had 
longer PFS than the whole population.7 Neutropenia was 
similar in both groups (26.7% versus 23.3%). Grade 3/4 
diarrhea occurred more frequently with the combination 
(15.2% versus 10.5%, respectively). Skin toxicity occurred 
more frequently with cetuximab treatment but was in the 
generally expected range (18.7% versus 0.2%).5 Findings 
from CRYSTAL suggest that combination treatment with 
FOLFIRI plus cetuximab expands the list of triplet combina-
tions that may be considered for ﬁ  rst-line therapy.7
Data on the impact of KRAS mutation on the results of 
this trial were eagerly anticipated, as it has been suggested 
that patients with mutated KRAS tumors do not beneﬁ  t 
from treatment with anti-EGFR inhibitors.8,9 Researchers 
analyzed archived tumor material from 540 KRAS-evaluable 
patients in the trial; these 540 were representative of the 
overall ITT population.10 Patients with wild-type KRAS 
who received cetuximab demonstrated signiﬁ  cantly greater 
PFS (P = 0.0167; HR, 0.68 [95% CI, 0.051–0.934]) and best 
overall response (59.3% for patients receiving cetuximab + 
FOLFIRI versus 43.2% for those receiving FOLFIRI alone). 
However, patients with mutant-form KRAS did not demon-
strate beneﬁ  t from cetuximab treatment in terms of either 
PFS (P = 0.75; HR,1.07 [95% CI, 0.71–1.61]) or best overall 
response (P = 0.46).
The EPIC study showed that the combination of cetux-
imab and irinotecan administered to patients with refractory 
mCRC as second-line therapy following oxaliplatin failure 
signiﬁ  cantly improved PFS and provided a superior quality 
of life versus irinotecan alone.11,12 In this phase III clinical 
trial, pretreated patients were randomly assigned to receive 
either cetuximab 400 mg/m2 followed by 250 mg/m2 weekly 
and irinotecan 350 mg/m2 every three weeks (n = 648) or 
irinotecan alone (n = 650). Although no difference in OS 
was noted between treatment arms, PFS and response rate 
were signiﬁ  cantly better with the addition of cetuximab, 
and the combination of cetuximab and irinotecan resulted 
in better quality of life when compared with cytotoxic 
therapy alone, with less deterioration in global health status 
scores and symptom scores (pain, nausea, insomnia).12 The 
most interesting result of this study seems to be the better 
response rate in second-line treatment when cetuximab was 
added to irinotecan: 16% of patients receiving cetuximab 
plus irinotecan demonstrated a partial response, versus 4% 
receiving irinotecan alone (P  0.0001). This ﬁ  nding is of 
particular interest for patients with potentially resectable liver 
metastases and those who have failed ﬁ  rst-line treatment with 
oxaliplatin-based chemotherapy.
In CO.17, a phase III randomized study of cetuximab 
and best supportive care (BSC) compared with BSC alone in 
patients with pre-treated EGFR-positive mCRC, conducted 
by the National Cancer Institute of Canada Clinical Trials 
Group in collaboration with the Australasian Gastro-Intestinal 
Trials Group, cetuximab administered as single-agent therapy 
to a patient population previously refractory to treatment was 
associated with signiﬁ  cantly improved OS and provided a 
superior quality of life, in comparison with BSC alone.13 
Median OS was 6.1 months with cetuximab plus BSC, 
versus 4.6 months for BSC alone (P = 0.0046).14 Cetuximab 
is commonly used in combination with irinotecan among 
patients with refractory disease; thus the results of this study 
will not change standard practice. However, for patients with 
poor tolerance to irinotecan, this study showed that cetuximab 
is active alone.
OPUS
The comparative efﬁ  cacy of FOLFOX4 plus cetuximab 
versus FOLFOX4 alone for initial treatment of previously 
untreated, unresectable mCRC was the focus of the OPUS 
(OxaliPlatin and cetUximab in ﬁ  rSt-line treatment of MCRC) 
trial.15 The primary outcome measure was overall response 
rate, deﬁ  ned as a decrease in tumor volume by 50% or more. 
Response rates favored FOLFOX plus cetuximab (45.6% 
versus 35.7%).15 Cetuximab administration was associated 
with a high rate of dermatologic toxicity (14.1%) and infu-
sion reactions; the latter, while noted in both treatment arms, 
were approximately twice as prevalent in the cetuximab 
group (4.1% versus 1.8%).16 The results of this study are 
less favorable than those reported in an earlier, phase II trial 
of the combination of FOLFOX and cetuximab, in which 
the conﬁ  rmed best overall response rate was 72% and the 
combination of cetuximab and FOLFOX-4 was generally 
well tolerated, with no evidence that cetuximab increased the 
frequency or severity of the characteristic toxicities associ-
ated with FOLFOX.17
In the OPUS trial, as in the CRYSTAL trial, KRAS status 
demonstrated a signiﬁ  cant inﬂ  uence on efﬁ  cacy.18 Investiga-
tors analyzed tissue from 233 patients, who were representa-
tive of the entire ITT population of the study. Patients with 
wild-type KRAS showed signiﬁ  cantly greater PFS when 
treated with cetuximab + FOLFOX versus FOLFOX only Clinical and Experimental Gastroenterology 2009:2 16
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(7.7 versus 7.2 months, respectively; HR, 0.57; P = 0.02); 
patients with KRAS mutation showed no signiﬁ  cant beneﬁ  t 
with the addition of cetuximab (5.5 versus 8.6 months; HR, 
1.83; P = 0.02). Patients with wild-type KRAS also showed 
signiﬁ  cantly greater response rates with the addition of 
cetuximab to FOLFOX (61% versus 37%; P = 0.01), while 
patients with KRAS mutation showed no signiﬁ  cant beneﬁ  t 
(33% versus 49%; P = 0.11).
Cetuximab hypersensitivity
Hypersensitivity reactions caused by cetuximab are a com-
mon, uncomfortable, and potentially unacceptable adverse 
effect. Intriguing data presented at ASCO 2007 suggest 
that these reactions may be mediated in many cases by 
pre-existing cetuximab-speciﬁ  c immunoglobulin E (IgE) 
antibodies (C–IgE). Investigators evaluated pre-treatment 
serum specimens from cetuximab-naïve mCRC patients 
and healthy volunteers.19 Of 71 cetuximab-treated subjects, 
21 (29.6%) experienced severe hypersensitivity, based on 
retrospective review of the medical record. In 15 of these 
patients, pretreatment sera were positive for C–IgE, and all 
15 discontinued therapy. The remaining six patients from 
this group had C–IgE-negative sera; four were rechallenged 
uneventfully, while two received no further exposure. 
Analyses of sera from healthy volunteers revealed that 15 of 
69 (21.7%) were C–IgE-positive. These data strongly suggest 
that C–IgE antibodies are present prior to treatment in a 
relatively high proportion of cetuximab-naïve subjects and 
are likely to be highly predictive of severe hypersensitivity 
reactions during cetuximab infusion.19
BICC-C
Updated efﬁ  cacy results were reported at ASCO20 and sub-
sequently published in Journal of Clinical Oncology21 for 
patients enrolled in the phase III randomized BICC-C study 
(n = 430 in period 1; n = 117 in period 2, following a protocol 
amendment adding bevacizumab to the FOLFIRI and irino-
tecan plus bolus 5-FU/LV [mIFL] study arms). In this trial, 
initial treatment of mCRC with FOLFIRI or FOLFIRI plus 
bevacizumab was superior to a range of comparator regimens. 
Results presented at ASCO 2007 included, in period 1, 
median PFS of 7.6 months for patients receiving FOLFIRI, 
5.9 months for mIFL (P = 0.004 for the comparison with 
FOLFIRI), and 5.8 months for capecitabine and irinotecan 
(CapeIRI) (P = 0.015). Median OS was 23.1 months among 
patients receiving FOLFIRI (with 75% of subjects surviving 
for at least one year), in comparison with 65% for mIFL and 
66% for CapeIRI. In period 2, median PFS was 11.2 months 
for FOLFIRI plus bevacizumab and 8.3 months for mIFL plus 
bevacizumab (P = 0.28).20 Median OS for patients receiving 
FOLFIRI plus bevacizumab had not been reached at the time 
of ASCO reporting; however, published results21 showed 
median OS of 28.0 months for patients receiving FOLFIRI 
plus bevacizumab, compared with 19.2 months for mIFL plus 
bevacizumab (P = 0.037; HR for death, 1.79; 95% conﬁ  dence 
interval [CI], 1.12–2.88). The 1-year survival rate was 87% 
for FOLFIRI plus bevacizumab, compared with 61% for 
mIFL plus bevacizumab. Grade 3 adverse events reported in 
period 2 included nausea (5.1%), diarrhea (11.9%), neutro-
penia (28.8%), and febrile neutropenia (1.7%). The median 
survival observed in this study is the best ever found in a 
trial of chemotherapy for metastatic colorectal cancer. With 
this combination, it now seems possible to break through the 
wall of 24-month survival that was previously considered 
very solid.
CAIRO: Comparing the efﬁ  cacy 
of sequential versus combination 
chemotherapy
Median OS in mCRC improves with exposure to 5-FU/LV, 
irinotecan, and oxaliplatin – highly active cytotoxic drugs 
comprising the foundation of contemporary chemotherapy.22 
No comparative data exist to determine whether exposure to 
sequential or combined use of these medications is preferred; 
similarly, the role of salvage treatments following failure 
of initial treatment has not been adequately studied in a 
prospective fashion. The Dutch Colorectal Cancer Group 
presented results at ASCO from the CAIRO (CApecitabine, 
IRinotecan, Oxaliplatin) study, the ﬁ  rst phase III trial to pro-
spectively evaluate sequential versus combination therapy 
in advanced CRC when all three cytotoxic drugs with known 
efﬁ  cacy are made available23 (subsequently published in 
Lancet).24
The CAIRO investigators randomly assigned 820 previ-
ously untreated patients to sequential treatment with ﬁ  rst-
line capecitabine, second-line irinotecan, and third-line 
capecitabine plus oxaliplatin (arm A) or to combination che-
motherapy with ﬁ  rst-line CapIRI and second-line capecitabine 
and oxaliplatin (CapOx) (arm B). The dose of capecitabine 
was 1250 mg/m2 (sequential) or 1000 mg/m2 (combination) 
twice daily on days 1 through 14, irinotecan 350 mg/m2 
(sequential) or 250 mg/m2 (combination), and oxaliplatin 
130 mg/m2. All cycles were administered every three weeks, 
with responses assessed every third cycle.24 Median follow-up 
was 32 months.24Clinical and Experimental Gastroenterology 2009:2 17
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Median OS, the primary endpoint, was 16.3 months 
with sequential therapy (95% CI, 14.3–18.1), which was 
not signiﬁ  cantly different from the 17.4 months achieved 
with combination therapy (95% CI, 15.2–19.2; log rank 
P = 0.3281).24 One-year survival rates were essentially identi-
cal (64%, sequential; 67%, combination). Overall grade 3/4 
toxicity across all lines did not differ signiﬁ  cantly except for 
grade 3 hand-foot syndrome (13% in arm A and 7% in arm B; 
P = 0.004). Speciﬁ  c grade 3/4 toxicities that were signiﬁ  cantly 
more frequent with combination treatment were diarrhea 
(P  0.0001), vomiting (P = 0.0002), nausea (P = 0.004), 
and neutropenia, including febrile neutropenia (P = 0.0001). 
Grade 3 hand-foot syndrome occurred signiﬁ  cantly more often 
in conjunction with sequential chemotherapy (P = 0.002). 
All-cause 60-day mortality was 3.0% (n = 12) in arm A and 
4.5% (n = 18) in arm B. The CAIRO ﬁ  ndings suggest that 
while combination therapy does not signiﬁ  cantly improve OS 
compared with sequential therapy, both treatment strategies 
are valid options for patients with advanced disease, given the 
high individual activity of the constituent cytotoxic agents.
The CAIRO and Fluorouracil, Oxaliplatin, and CPT11 
(irinotecan) – Use and Sequencing (FOCUS) trials clearly 
demonstrate that it is possible to give ﬁ  rst-line monotherapy 
to selected patients. In the FOCUS study, among 2135 treat-
ment-naïve patients with advanced CRC, initial single-agent 
treatment upgraded to combination upon progression was 
noninferior to ﬁ  rst-line combination treatment, with median 
survival of 13.9 months.25 However, only the combination 
of ﬂ  uorouracil and irinotecan satisﬁ  ed the statistical test 
for superiority, achieving median survival of 16.7 months 
(P = 0.01). These concordant trials suggest that sequential 
treatment is an alternative option for discussion with patients 
that should be considered, especially for those with deﬁ  nitely 
nonresectable disease (ie, a combination of peritoneal carci-
nomatosis and liver metastases).
BRiTE
The BRiTE (Bevacizumab Regimens: Investigation of Treat-
ment Effects and Safety) observational study reported on 
the utility of continuing ﬁ  rst-line bevacizumab in salvage 
therapy for tumor progression.26 Using observational data 
from a registry encompassing nearly 2000 patients with 
mCRC receiving bevacizumab and ﬁ  rst-line chemotherapy, 
the investigators assessed the effects on PFS and OS 
of continuing bevacizumab beyond progression (BBP), 
correcting for a range of pre- and posttreatment patient factors. 
First progression was documented in 1369 patients, occur-
ring at a median follow-up of 17.5 months. In patients with 
progression, 65.2% received second-line chemotherapy with 
an approved agent, 34.8% received cetuximab, and 53.8% 
received BBP. While no chemotherapy sequence or combi-
nation predominated, multivariate analysis suggested that 
BBP or administration of any second-line chemotherapy was 
signiﬁ  cantly associated with increased OS (P  0.0001).26 
As with the CAIRO study, ﬁ  ndings from the BRiTE registry 
emphasize that improved survival corresponds with exposure 
to all active agents.
Chemotherapy in elderly patients
The pervasive underrepresentation of elderly patients in 
clinical trials was the impetus for a phase II study of twice-
monthly FOLFIRI administered to mCRC patients more 
than 70 years of age who were in otherwise good general 
condition.27 This analysis reported satisfactory efficacy 
and tolerability ﬁ  ndings in 40 chemotherapy-naïve patients 
(median age, 77.3 years; range, 70–84.7 years) with perfor-
mance status of 0 to 1. Eleven patients were more than 80 years 
of age. Thirty-four patients (85%) presented with one or more 
concomitant chronic conditions, and 23 patients (58%) had 
at least three comorbid diseases. Patients received FOLFIRI 
every two weeks. In an intent-to-treat analysis, the objective 
response rate was 32.5% (95% CI, 18.6%–49.1%), including 
two complete responses and 11 partial responses. Median time 
to progression was 8.0 months, median OS was 14.2 months, 
and speciﬁ  c OS time was 18.6 months. Main toxicities were 
grade 3/4 diarrhea (n = 13; 32.5%), asthenia (n = 6, 15%), 
nausea (n = 3, 7.5%), and neutropenia (n = 3, 7.5%). One 
death was attributable to grade 4 diarrhea. Mean quality of 
life score, assessed using the Spitzer visual uniscale, increased 
from 75 at baseline to 87 at cycle 12 (P = 0.005).27
Another presentation focusing on elderly patients was 
an updated meta-analysis of randomized trials evaluating 
5-FU/LV with or without irinotecan in which, using original 
source data, the investigators compared the efﬁ  cacy and 
toxicity of such treatment in older (70 years) and younger 
patients (70 years) with mCRC.28
A total of 2691 patient records were evaluated and clearly 
indicated that elderly patients enrolled in phase III trials 
derive beneﬁ  ts from irinotecan-containing chemotherapy 
comparable to those of younger patients, without excess 
risk of toxicity. Older and younger subjects demonstrated 
signiﬁ  cantly improved response rates and PFS with irinotecan 
plus 5-FU/LV compared with 5-FU/LV alone. Younger 
patients had signiﬁ  cantly longer OS with irinotecan plus 
5-FU/LV, while older patients demonstrated a trend to 
longer OS with irinotecan plus 5-FU/LV. There were no Clinical and Experimental Gastroenterology 2009:2 18
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signiﬁ  cant differences regarding irinotecan plus 5-FU/LV 
toxicity between older and younger patients.28 These two 
trials clearly show that it is possible to administer aggressive 
chemotherapy to elderly patients. The suitability of these 
patients for chemotherapy has to be cautiously determined, 
but after this ﬁ  rst step, there is no reason to decrease the 
intensity of chemotherapy in elderly patients.
Conclusion
Presentations at ASCO 2007 afﬁ  rm that the steady accumula-
tion of evidence continues upon which to base pharmacother-
apy for metastatic colorectal cancer. While no report from this 
recent assembly, except the EPOC study, can be said to have 
immediate implications for changing clinical practices, it can 
also be said that the current foundations of care – irinotecan, 
oxaliplatin, 5-FU, and to an increasing extent the targeted bio-
logic agents bevacizumab and cetuximab – continue unchal-
lenged as ﬁ  rst-line and later therapy selections. It now seems 
possible to give cetuximab in the ﬁ  rst line to patients with 
mCRC. However, knowing the results of biologic determinants 
of efﬁ  cacy such as KRAS is necessary to choose the best popu-
lation to treat with this agent. This ASCO meeting did not add 
information for the administration or efﬁ  cacy of bevacizumab, 
except that the BICC-C trial gave us the opportunity to see 
the best median overall survival results ever encountered in 
nonselected patients with metastatic colorectal cancer.
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